Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Zydus Cadila gets...

    Zydus Cadila gets USFDA nod for generic cholesterol drug

    GarimaWritten by Garima Published On 2018-11-23T12:15:00+05:30  |  Updated On 23 Nov 2018 12:15 PM IST
    Zydus Cadila gets USFDA nod for generic cholesterol drug




    New Delhi: Drug maker Zydus Cadila Thursday said it has received approval from the US health regulator to market cholesterol-lowering drug Atorvastatin Calcium tablets. The Ahmedabad-based group has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 10 mg, 20 mg, 40 mg and 80 mg, Zydus Cadila said in a statement.

    The product will be manufactured at its formulations facility at Moraiya, Ahmedabad, it added.

    Atorvastatin is used along with a proper diet to help lower bad cholesterol and fats and raise good cholesterol (HDL) in the blood. It belongs to a group of drugs known as statins.

    Zydus Cadila said it has also received a tentative approval for Dimethyl Fumarate Delayed-Release Capsules, which is indicated for the treatment of relapsing forms of multiple sclerosis.

    Shares of Cadila Healthcare, the listed entity of the group, were trading 1.47 per cent down at Rs 353 per unit on the BSE.

    Also Read: Zydus Cadila gets USFDA nod to market generic Deferasirox tablets






    AhmedabadapprovalAtorvastatinBSEcalcium tabletscholesteroldimethyl fumaratedrugdrugmakerfatsgenericHealthcaremedicinerelease capsulesclerosisstatinsUSFDAZydus Cadila
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok